• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine; of the formula (I): <CHEM> wherein: R<1> is C5-C7 cycloalkyl, thienyl, halothienyl, (C1-C4 alkyl)thienyl, furanyl, pyridyl or thiazolyl; <CHEM> each of R<2> and R<3> independently is hydrogen or methyl;
    公开号:SU1598865A3
    申请号:SU874203804
    申请日:1987-12-17
    公开日:1990-10-07
    发明作者:Вейн Робертсон Дэвид；Тайвай Вонг Дэвид；Герман Крушински Джозеф (Мл.)
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to novel 3-aryloxy-3-propanamine derivatives having pharmacological activity and which can be used as inhibitors of serotonin and norepinephrine absorption.
    The aim of the invention is a method for the preparation of new 3-aryloxy-3-substituted propanamines, as well as their pharmacologically acceptable acid addition salts, possessing a higher inhibitory activity on the absorption of serotonin and norepinephrine, i
    EXAMPLE 1. C-Methyl-3- (1-naphtalynyloxy) -3- (2-thienyl) propane-aminoxalate (compound 1).
    Phenyl chloroformate (794 μl, 0.0063 mol) is added dropwise to a refluxed solution of H, K-dimethyl-3- (1-naphthaleneloxy) -3- (2-thienyl) propanamine (1.79 g , 0.0058 mol) in 100 ml of toluene. The resulting solution is heated under reflux for 1.5 hours and cooled to room temperature. Solution solution 2.5 n. sodium hydroxide solution, water.
    sd
    oh
    00
    35 SP

    CM
    1n. a solution of hydrochloric acid, brine, dried in the presence of anhydrous sodium sulfate and concentrated in vacuo to obtain 2.4 g of crude carbamate, 5 n. sodium hydroxide solution (11.5 ml, 0.058 mol) was added to the carbamate solution (2.4 g, 0.0058 mol in propylene glycol (100 ml). The mixture was heated at 110 ° C for 75 minutes. The reaction mixture was diluted with water and extracted with diethyl ether. The organic phase is washed with water and then with a saturated sodium chloride solution, dried in the presence of anhydrous sodium sulfate, and concentrated in vacuo to give 1.5 g of oil. Crystallization of the oil as an oxalic acid salt from mixtures of ethyl acetate and methanol result in 920 mg (41.3%) of compound 1 as a white powder, m.p. 136 - 138.54.
    EXAMPLE 2 N-Methyl-3-4- (tri-fluoromethyl-1-naphthalenyloxy) J-3- (2-thienyl) propanaminoxalate (compound 2).
    In accordance with the procedure described in Example 1, M, N-dimethyl-3-4- (trifluoromethyl-1-naphthalenyloxy) -3- (2-thienyl) propanaminoxalate is converted to compound 2. Crystallization from a mixture of ethyl acetate and methanol leads to obtain 430 mg (33.8%) of brown powder, so pl. 154-15b with.
    Froze H-Methyl-3- (1-naphthalenyloxy) -Z- (3-thienyl) propanaminoxalate (compound 3).
    Compound 3 is prepared according to the procedure described in example 1, from N, M-dimethyl-3- (1-naphthalenyloxy) -3- (3-thienyl) propanamine. Crystallization from a mixture of ethyl acetate and methanol gives 2.97 g (63.6%) of a white powder, m.p. 148 - 150 ° C.
    Found,%: C 62.23; H 5.59; N 3.85.
    C.H.NOjS. .
    Calculated,%: C 62.00; H 5.46: N 3.62.
    Example 4. H-Methyl-3- (4-chloro-1-naphthalenyloxy) -3- (2-thienyl) propane amino oxalate (compound 4).
    To a mixed solution of H, N-dimethyl-3- (4-chloro-1-naphthylyl-1oxy) -3- (2-thienyl) propanamine (2.81 g.
    8.12 mmol) and 20 ml of toluene, heated at 85 ° C, are added dropwise trichloroethyl formate (1.89 g, 8.93 mmol). Stirring is continued at 85 ° C for 3 hours and the resulting solution is cooled in an ice bath. About 13 ml of 98% formic acid was added to the mixture, followed by the addition of 0.28 mp of triethyl amine. The mixture is stirred at room temperature for 30 minutes. The mixture was poured into water, and the mixture was extracted with diethyl ether. The organic extracts are washed sequentially with a saturated solution of sodium chloride, 2N. a solution of hydrochloric acid and a saturated solution of sodium chloride. The organic phase is dried in the presence of anhydrous sodium sulphate. The volatiles were evaporated in vacuo to give 3.63 g (92% yield) of crude carbamate as an oil. 98% formic acid (0.69 g, 0.9 m of dimethylformamide (.TMP) was added to the solution of carbamate in 10.0 m 14.9 mmol). The reaction solution is cooled to 15 ° C. under a nitrogen atmosphere. Then, zinc dust (1.22 g, 18.8 mmol) was added in portions over a 30-minute period. The mixture was stirred at reflux for 1 hour and then overnight at room temperature. The reaction mixture was filtered through a sintered glass funnel, and the filtrate was diluted with water. The acidic solution is made basic through an excess of cold ammonium hydroxide solution and then extracted with diethyl ether. The organic extracts are washed with water and then with a high-grade sodium chloride solution. The organic phase is dried over anhydrous sodium sulphate and evaporated in vacuo. The residue is purified by preparative HPLC using a silica gel column with a mixture of methylene chloride, methanol and ammonium hydroxide (100: 5: 1 vol.) As eluent, thus obtaining 1.26 g (51% yield) of the free base as an oil. The salt of oxalic acid is obtained from the free base by treating a solution of ethyl acetate with a free base with oxalic acid. The precipitate is crystallized from methanol to obtain colorless crystals, so pl. 132 ° g; (with decomposition),
    5 1598865
    Found,%: C 57.22; fl 4.54; Found,%: C 50.40; H 4.66;
    N 3.48 .. N 3 72.
    C ,, H ,,. С, И „КО, 8.
    Calculated,%: C 56.94; H 4.78; Calculated,%: C 50.37; H 4.48;
    N 3.32. . „5 N 3.46.
    PRI me R 5. N-Me. Methyl-3- (4-me-PRI me R 10. N-Methyl-3- 4- (trityl-1-naphthalenyloxy) -3- (2- thienyl) -fluoromethyl) fbnoxy-3- (3-thienyl) propanoamine maleate (compound 5). .Panaminoxalate (compound 10),
    The free base of the compound so pl. 181-182 C.
    get at the output of 44% with the use of Found,%: from 40.49; H 4.42;
    method described in example-N 3 67.
    re 4. Salt of maleic acid semi-CH F N0 S.
    from the male base free base /%: C, 50.37; H 4.48; new acid. The resulting precipitate is} 5 N 3 46.
    recrystallized from ethanol with, according to PRI me R 11. K-Methyl-3-G4- (trichlorination. colorless crystals, mp. fluoromethyl) phenoxy-3- (2-furankl) pro174 C (with decomposition) .Panaminoxalate (compound 11), so pl.
    Found,%: C 64.49; H 5.71; 98-102 s (with decomposition).
    g P MP s Found,%: C 52,52; H 4.45;
    Чз-Ч 5 .N 3,80.
    Vytseleno,%: C 64,62; H 5.89; p c v kgp
    m -3 00 and
     D Calculated,%: C 52.45; H 4.66;
    The following compounds are obtained in 3 60
    according to the methods outlined 25 p and m 12. 12. N-Methyl-3- (4-mev examples 1 and 2. o / p
     , chtilphenoxy) -3- (2-thienyl) propanaminoLp and meper 6-.-) - M-Metsh1-3- (1- (compound 12), mp. 152 naphthaleneloxyloxy) -3- (2- thienyl) propane C
    amino maleate. (compound 6), so pl. 118-per gene,%: C 58.05; H 6.04
     (j, jQ m 79
    U 3.82% UJ 091 C at C ,, H ,, NO, S.
     in methanol. - listed as% i С 58,10; H 6.02;
    Found,%: C 63.78; H 5.44; m qq
    m Q QS. C 7 JIN j.
    C H NO SP p and MER 13. H-Metsh-3- (4-chloro g-yr, 5 -l phenoxy) -3- (2-thienyl) propanamino Calculated%: C 63.90; H 5.61; (compound 13), so pl. 126JN j, jy; L 7.75.129 G
    EXAMPLE 7: N-Metsht-3- (1-naphtha-. Found,%: C 51.60; H 5.01;
    linyloxy) -3-cyclohexylpropanamine-N 3 52 lettuce (compound 7), so pl. 184-185 ° C. п Г Н ПНО-Ч
    On, e „„. 7 .: C 68.36; "7.30, t with 51.68, H 4.88,
     N T 77
    GNMPHJ, //.
     g -ge —Example 14. S-Methyl-3- (4-Me Acupuncture,%: C 68.20; H 7.54; toxophenoxy) -3- (2-thienyl) propanamine JL „45 oxalate (compound 14) , m.p., 130P R m i r 8. M-metip-3- (1-naphthyl-
    insloxy) -3- (2-thiazolsht) propanamine-Found,%: C 55.31; H 5.55;
    oxalate (compound 8, mp. 183 m l hfT
    185 s. . .
    Found,%: C 59.02; H 4.94; 50
    N 7.47 ..
    CtgHjoN OjS. .Calculated% C 55.57; H 5.76;
    Calculated,%: C 58.75; H 5.19; N 3.81.
     7.21. EXAMPLE 15 M-Methyl-3- (1-naphf Talinsch-1 Oxy) -3- (2-furanyl) propane. Example 9. H-Methyl-3-14- (tri-aminoxalate (compound 15), t. PC,
    fluorometsht) phenoxy-3- (2-thienyl) pro-145-14b with.
    panaminoxalate (compound 9), mp. Found,%: C 64.79; H 5.51;
    167-168 s (with decomposition) .N 3,95.
    C ,, N ,, MOB.
    Calculated,%: C 64.68; H 5.70; N 3.77.
    PRI me R 16. K-Methyl-3-E4- (trifluoromethyl) phenoxyJ-3- (cyclohexyl) propanamine amino acid (compound 16), m.p. 212-213 p.
    Found,%: C 56.19; H 6.37; N 3.32.
    S, UH ..
    Calculated,%: C 56.29; H 6, A6; N 3.45. . .
    Example 17. N-Methyl-3-ST-naphtapinyl oxy) -3- (3-pyridyl) propanamine oxalate (compound 17), mp. (with decomposition).
    Found,%: C 64.27; H 5.67; N 7.01.
     C ,, I4aNa05, Calculated,%: C 65.96; H 5.80; N 7.35.
    Example 18. (+) - M-Methyl-3- (1-naphthalenyloxy) -3- (2-thienyl) propanaminoxalate (compound 18), mp. 133-134 ° C.
    Found,%: C 62.0; H 5.51; N 3.87.
    C ,, I4 ,.
    Calculated,%: C 62.00; H 5.46; N 3.62.
    Example 19. (-) - K-Metip-3- (1- naphthapynyloxy) -3- (2-thionyl) propanaminoxalate (compound 19), mp. 138-138 ,.
    Found,%: C 61.72; H 5.32; N 3.82.
    , N (VS.Calculated,%: C 62.00; H 5.46; N3.62.
    The proposed compounds are useful for inhibiting the uptake of serotonin and norepinephrine.
    Pharmacological activity of the proposed compounds.
    Male Sprague-Dawley rats (110150 g) were fed for at least 3 days before being used in the studies. Rats were killed by decapitation. Then they took out and dissected all brains. The cerebral cortex was homogenized in 9 volumes of medium containing 0.32 M sucrose and 10 m11 glucose. Untreated synaptosomal preparations were isolated after differential centrifugation at 1000 g for 10 min and 17000 g for 28 min. The final sediments were suspended in the same
    medium and kept in ice before use on the same day.
    Synaptosomal Absorption of ZN-gray-5 tonin (ZN-5-Hydroxytryptamine, ZN-5GT) and 14C-1-norzpinephrine (14C-HE) was determined as follows. Cortical synaptosomes (equivalent to 1 mg of protein) were incubated at 0–37 ° C for 5 min in 1 ml of Krebs-bicarblate-containing medium also containing 10 mM glucose, 0.1 mM proniazide, 1 mM ascorbic acid, mM EDTA, 50 nM 3H-5FT and 100 nM 14C-NOT. 5 The reaction mixture was diluted with 2 mp ice-cold Krebs-bicarbonate buffer solution and filtered under vacuum. Filters were washed twice with approximately 5 ml of 0.9% saline cooled on ice and transferred to a counting tube containing 10 ml of scintillation fluid. Radioactivity was measured with a liquid-scintillation spectrophotometer 5 photometer. The accumulation of ZN-5GT and 14C-NOT at 4 ° C was the background and was subtracted from all samples.
    The results of the evaluation of the proposed compounds are presented in the table, 0 where the structure of the compounds, the form of the salt, the concentration of the test compound (IC, j.p) at (nM) are indicated, are necessary to: inhibit 50% of serotonin or norepinephrine, respectively. Numbers in parentheses (round) represent percent inhibition at 10,000 nM.
    Activity comparisons were made with N-methyl-3- (4-trifluoromethyl) -fe-0-noxy-3-cyclopropylpropanamine. Compounds subjected to inhibition in the uptake of () seroto-Nina and norepinephrine, nM: ITN-5 GT 14C-NE
    5 Suggested compound 1679 285. Known compound. some 100 2500 From the data presented, it is clear that Q that the proposed compound is more effective in its ability to inhibit the uptake of serotonin and norepinephrine, and also represent more balanced compounds in their ability to inhibit both mono-amines. The proposed compounds have improved toxicity and can be classified as low-TOXIC1X.
    9, 1598865
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    to to
    The method of obtaining 3-aryloxy-3-substituted propanamines of formula
    R-CHCHg,
    About i
    Ag
    each R is halogen, C, -C-alkyl, C, -C j-alkoxy or trifluoromethyl; each Ry is halogen. C, -C-alkyl or
    trifluormetesh Ja 0.1 or 2; p O or 1,
    Where. R is C5-C7-1CHChlochloalkyl, thienyl,
    furanyl, pyridyl, or thiazolyl;
    Arg group: - J Ip or j J
    or their pharmaceutically acceptable acid addition salts, in which the compound of formula (I), where both Rj and Rj are methyl, is demethylated and the target product is isolated as free
    a base or pharmacologically acceptable with 1 substandard acid addition salt,
    where one of Rj and Rj is hydrogen, and the other is methyl; Inhibition in vitro uptake of 5HT and norepinephrine
    Ri-CHCH CH NR2R3 O
     A
    ten
    R is halogen, C, -C-alkyl, C, -C j-alkoxy or trifluoromethyl; Ry is halogen. C, -C-alkyl or
    trifluormetesh Ja 0.1 or 2; p O or 1,
    OOh /
    f
    s
    f s /
    Cr
    r-s
    L (
    Q
    CHjN
    95
    (46)
    CHjH 18
    69
    CHj H Oxalat A9
    77
    CH, H Maleat 33
    47
    CHj. H Oxalate 125 30
    CH, H 79 205
    CHj H 46 (52)
    CH,
    H Oxalat 100
    (36)
    eleven
    1598865.
    eleven
    SNS
    About s
    12
    ABOUT
    13
    QI j) axis.
    fv h
    T-CH, H-Oxalate 20
    ABOUT
    SN, H 79
    Tg
    & -
    fyT gos,
    18
    fy
    S
    12
    Table continuation
    .. H 112
    H 91
    H.50
    N-Oksalat 20
    H 79
    H 30
    H 12.3 N Oxalate 21.5
    22
    59
    260
    22.7 285
    thirty
    38 34
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1598865A3|1990-10-07|Method of producing 3-aryloxy-3-substituted propane amines or their pharmaceutically acceptable acid-additive salts
    US4820873A|1989-04-11|Pyrene derivatives
    US4675319A|1987-06-23|Antianaphylactic and antibronchospastic piperazinyl-|carboxamides, compositions and use
    JP3545416B2|2004-07-21|Huperzine A derivatives, their production and their use
    US4719046A|1988-01-12|Crysene derivatives
    US4719048A|1988-01-12|Crysene compound
    JP2000511556A|2000-09-05|Novel water-soluble C-ring analog of 20 | -camptothecin
    SU1148563A3|1985-03-30|Method of obtaining derivatives of 2-|-or 2-|ethylamine
    CA1222517A|1987-06-02|Tetrazole pharmaceutical derivatives
    US4439436A|1984-03-27|1,3-Dioxolo|quinoline compounds
    US4946862A|1990-08-07|Thiophene derivative and process for preparing the same
    AU640831B2|1993-09-02|Process for preparing benzo|phenanthridinium derivatives, and novel compounds prepared by said process
    US4287211A|1981-09-01|Derivatives of phenylethylamines, processes for their preparation and related pharmaceutical compositions
    EP0182608A2|1986-05-28|Polycyclic compounds, their preparation and formulations containing them
    SU1282821A3|1987-01-07|Method of producing tylosine derivatives
    JP2000511897A|2000-09-12|Novel water-soluble analog of 20 | camptothecin
    SU569287A3|1977-08-15|Method of preparation of benzhydryloxyalkylamine derivatives or salts thereof
    US4252810A|1981-02-24|9,10-Dihydro-4H-benzo[4,5]cyclohepta [1,2-b]thiophen-4,9-imines
    Costa et al.1974|Pentaatomie heteroaromatic cations. Note III. A Convenient Synthesis of Aldehydes from Carboxylic Acids via 2‐Substituted 1, 3‐Benzoxathiolium Perchlorates
    CA1095914A|1981-02-17|4-hydroxy-2-quinolinone-3-carboxylic acid compounds
    US4452982A|1984-06-05|Process for the preparation of nitrogen-bridgehead condensed pyrimidine compounds, and pharmaceutical compositions containing them
    SE453293B|1988-01-25|3,3-DIALKYL AND 3,3-ALKYLENE-INDOLINE DERIVATIVES, SET FOR PREPARING THESE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Tamura et al.1974|Mono‐N‐amino salt of benzodiazines and naphthyridines
    US4829090A|1989-05-09|Chrysene derivatives
    US4866073A|1989-09-12|Acridinylmethylamino derivatives and pharmaceutical compositions containing them
    同族专利:
    公开号 | 公开日
    DE122005000002I1|2005-05-12|
    EG18230A|1992-10-30|
    JPS63185946A|1988-08-01|
    AU591007B2|1989-11-23|
    EP0273658A1|1988-07-06|
    IE873449L|1988-06-22|
    DK664887D0|1987-12-17|
    NL300171I2|2005-06-01|
    JP2549681B2|1996-10-30|
    DK174599B1|2003-07-14|
    LU91131I2|2005-03-29|
    PT86389A|1988-01-01|
    ZA879472B|1989-08-30|
    DK664887A|1988-06-23|
    AR243868A1|1993-09-30|
    CA1302421C|1992-06-02|
    SG114992G|1993-01-29|
    AU8266087A|1988-06-23|
    ES2019949B3|1991-07-16|
    NL300171I1|2005-04-01|
    CN1019113B|1992-11-18|
    IL84863A|1992-03-29|
    PH26556A|1992-08-19|
    HK69693A|1993-07-30|
    EP0273658B1|1990-10-31|
    KR880007433A|1988-08-27|
    HU206309B|1992-10-28|
    GR3001207T3|1992-07-30|
    CY1682A|1993-10-10|
    PT86389B|1990-11-20|
    HUT47561A|1989-03-28|
    CN87108175A|1988-07-06|
    AT57924T|1990-11-15|
    NZ222980A|1989-11-28|
    MX9845A|1993-12-01|
    IL84863D0|1988-06-30|
    DE3765919D1|1990-12-06|
    KR960003808B1|1996-03-22|
    DE122005000002I2|2006-08-24|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2842555A|1954-07-27|1958-07-08|Burroughs Wellcome Co|Method of preparing quaternary salts of amino carbinols|
    AT255400B|1965-03-22|1967-07-10|Chemie Linz Ag|Process for the production of new basic ethers|
    US3423510A|1966-08-31|1969-01-21|Geigy Chem Corp|3- - 3 - (2'-pyridyl-n-methylpropylamine for the treatment of depression|
    US4018895A|1974-01-10|1977-04-19|Eli Lilly And Company|Aryloxyphenylpropylamines in treating depression|
    FR2482956B1|1980-05-22|1983-11-18|Synthelabo|US4902710A|1988-12-14|1990-02-20|Eli Lilly And Company|Serotonin and norepinephrine uptake inhibitors|
    FI912280A|1990-05-17|1991-11-18|Lilly Co Eli|KIRAL SYNTES AV 1-ARYL-3-AMINOPROPAN-1 -OLER.|
    EP0571685A1|1992-05-27|1993-12-01|Novo Nordisk A/S|Aryloxyheteroarylpropylamines, their preparation and use|
    US5362886A|1993-10-12|1994-11-08|Eli Lilly And Company|Asymmetric synthesis|
    TW344661B|1993-11-24|1998-11-11|Lilly Co Eli|Pharmaceutical composition for treatment of incontinence|
    JP4625637B2|2002-02-22|2011-02-02|シャイアエルエルシー|Active substance delivery system and method for protecting and administering an active substance|
    GB0004153D0|2000-02-23|2000-04-12|Astrazeneca Uk Ltd|Novel use|
    GB0004149D0|2000-02-23|2000-04-12|Astrazeneca Uk Ltd|Novel compounds|
    GB0004151D0|2000-02-23|2000-04-12|Astrazeneca Uk Ltd|Novel use|
    GB0004152D0|2000-02-23|2000-04-12|Astrazeneca Uk Ltd|Novel compounds|
    CA2452347A1|2001-07-31|2003-02-13|Pharmacia & Upjohn Company|Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines|
    SE0102640D0|2001-07-31|2001-07-31|Astrazeneca Ab|Novel compounds|
    EP1486493A4|2002-03-19|2007-04-04|Mitsubishi Chem Corp|3-hydroxy-3-propionamide compound, process for producing the same, and process for producing 3-amino-1--1-propanol compound therefrom|
    US7659409B2|2002-03-19|2010-02-09|Mitsubishi Chemical Corporation|3-Hydroxy-3- propionamides and production method thereof, and production method of 3-amino-1--1-propanols using the same|
    WO2003097632A1|2002-05-20|2003-11-27|Mitsubishi Rayon Co., Ltd.|Propanolamine derivatives, process for preparation of 3-n-methylamino-1--1-propanols and process for preparation of propanolamine derivatives|
    DE10235206A1|2002-08-01|2004-02-19|Basf Ag|Process for the preparation of-3-methylmino-1-propan-1-ol|
    GB0220581D0|2002-09-04|2002-10-09|Novartis Ag|Organic Compound|
    GB0229583D0|2002-12-19|2003-01-22|Cipla Ltd|A process for preparing duloxetine and intermediates for use therein|
    DE10302595A1|2003-01-22|2004-07-29|Basf Ag|New 3-methylamino-1-thienyl-1-propanone, useful as intermediate for the pharmaceutical N-methyl-3- 1-naphthyloxy-3-thienyl-propylamine|
    DE10345772A1|2003-10-01|2005-04-21|Basf Ag|Process for the preparation of 3-methylamino-1--propan-1-ol|
    DE102004004719A1|2004-01-29|2005-08-18|Basf Ag|Process for the preparation of enantiomerically pure aminoalcohols|
    KR101160502B1|2004-02-19|2012-06-28|론자 아게|Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols|
    DE102004022686A1|2004-05-05|2005-11-24|Basf Ag|Process for the preparation of optically active alcohols|
    GB0410470D0|2004-05-11|2004-06-16|Cipla Ltd|Pharmaceutical compound and polymorphs thereof|
    AR049401A1|2004-06-18|2006-07-26|Novartis Ag|AZA-BICICLONONANS|
    GB0415746D0|2004-07-14|2004-08-18|Novartis Ag|Organic compounds|
    EP1784381A1|2004-08-26|2007-05-16|Neurosearch A/S|Novel substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors|
    EP1730132A2|2004-12-23|2006-12-13|Teva Pharmaceutical Industries Ltd|Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof|
    WO2006099457A1|2005-03-14|2006-09-21|Teva Pharmaceutical Industries Ltd.|-n,n-dimethyl-3--3- propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof|
    GB0507298D0|2005-04-11|2005-05-18|Novartis Ag|Organic compounds|
    WO2007011820A2|2005-07-15|2007-01-25|Amr Technology, Inc.|Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin|
    DE102005044736A1|2005-09-19|2007-03-22|Basf Ag|New dehydrogenases, their derivatives and a process for the preparation of optically active alkanols|
    EP1838692A2|2005-09-22|2007-10-03|Teva Pharmaceutical Industries Ltd|Dnt-maleate and methods of preparation thereof|
    ITMI20051970A1|2005-10-18|2007-04-19|Solmag S P A|PROCESS FOR THE PREPARATION OF MIXED HETERENTS DERIVING FROM INHTHOLE AND INTERMEDIATES OF CRYSTALLINE FORMS DEFINED BY + E - DULOXETINE|
    DE602006009138D1|2005-11-30|2009-10-22|Hoffmann La Roche|3-AMINO-2-ARYLPROPYLAZAINDOLE AND APPLICATIONS THEREOF|
    EP2100888A3|2005-12-05|2011-01-19|Teva Pharmaceutical Industries Ltd.|Process for the preparation of duloxetine hydrochloride|
    GB0525673D0|2005-12-16|2006-01-25|Novartis Ag|Organic compounds|
    GB0525672D0|2005-12-16|2006-01-25|Novartis Ag|Organic compounds|
    DE102005062662A1|2005-12-23|2007-06-28|Basf Ag|Preparation of optically active alkanol compound, useful for the treatment of depression or incontinence, comprises incubating an enzyme with a polypeptide sequence in a medium containing alkanone compound and isolating|
    DE102005062661A1|2005-12-23|2007-08-16|Basf Ag|Process for the preparation of optically active-3-chloro-propan-1-ol|
    CZ299270B6|2006-01-04|2008-06-04|Zentiva, A. S.|Process for preparing -N-methyl-3--3-propylamine hydrochloride|
    US8362279B2|2006-01-06|2013-01-29|Msn Laboratories Limited|Process for pure duloxetine hydrochloride|
    CN101657438A|2006-12-22|2010-02-24|斯索恩有限公司|The method for preparing duloxetine and related compound|
    CN105566284A|2008-04-11|2016-05-11|尼克塔治疗公司|Oligomer-aryloxy-substituted propanamine conjugates|
    EP2133072A1|2008-06-13|2009-12-16|KRKA, D.D., Novo Mesto|Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives|
    CN101613347B|2008-06-23|2012-07-04|中国人民解放军军事医学科学院毒物药物研究所|Amine compound and medical application thereof|
    HU230480B1|2008-07-25|2016-07-28|Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag|Process for producing n-methyl-aryloxy-propan-amine derivatives|
    HUE026181T2|2008-08-27|2016-05-30|Codexis Inc|Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine|
    WO2010025287A2|2008-08-27|2010-03-04|Codexis, Inc.|Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine|
    MX2011011900A|2009-05-12|2012-01-20|Squibb Bristol Myers Co|CRYSTALLINE FORMS OF -7--4 --1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF.|
    SG175420A1|2009-05-12|2011-12-29|Albany Molecular Res Inc|7--4--1,2,3,4- tetrahydroisoquinoline and use thereof|
    CZ304602B6|2009-09-02|2014-07-30|Zentiva, K. S.|Crystallization process of -N-methyl-3--3-propylamine hydrochloride |
    EP2377525A1|2010-03-26|2011-10-19|Laboratorios del Dr. Esteve S.A.|Duloxetine enteric pellets|
    SI2558455T1|2010-04-13|2017-12-29|Krka, D.D., Novo Mesto|Synthesis of duloxetine and/or pharmaceutically acceptable salts thereof|
    EP2606049A4|2010-08-17|2014-01-08|Albany Molecular Res Inc|2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin|
    EP2508519A1|2011-04-07|2012-10-10|Bioindustria Laboratorio Italiano Medicinali S.p.A In forma abbreviata Bioindustria L.I.M. S.p.A.|"Process for the preparation of duloxetine and its hydrochloride salt"|
    GR1007725B|2011-10-17|2012-10-18|Φαρματεν Αβεε,|Process for the preparation of highly pure duloxetine hydrochloride|
    PL224543B1|2013-08-21|2017-01-31|Pabianickie Zakłady Farm Polfa Spółka Akcyjna|Duloxetine enteric tablet|
    US9668975B2|2014-10-14|2017-06-06|PharmaDax Inc.|Method of preparing drug agglomerate|
    CN105777706B|2014-12-25|2019-08-23|江苏恩华药业股份有限公司|A kind of 3- [-oxygroup] -3- arylprop aminated compounds and its application|
    JP2016222628A|2015-06-03|2016-12-28|株式会社トクヤマ|Method for producing duloxetine hydrochloride|
    JP6182183B2|2015-07-07|2017-08-16|東和薬品株式会社|Method for producing duloxetine base and duloxetine hydrochloride|
    CN106349211B|2016-08-26|2020-10-16|江苏恩华药业股份有限公司|2-methyl-3-aryloxy-3-heteroaryl propylamine compound and application thereof|
    EP3339304A1|2016-12-20|2018-06-27|Laboratorios del Dr. Esteve, S.A.|Quinoline and isoquinoline derivatives for treating pain and pain related conditions|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US94512286A| true| 1986-12-22|1986-12-22|
    [返回顶部]